



TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

		Application Number	09/989,722
		Filing Date	November 19, 2001
		First Named Inventor	Ashkenazi, et al.
		Group/Art Unit	1647
		Examiner Name	Wegert, Sandra
Total Number of Pages in This Submission		Attorney Docket Number	39780-2730P1C63

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input type="checkbox"/> Version with Markings Showing Changes <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> Request for Refund	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (<i>Appeal Notice, Brief, Reply Brief</i>) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Additional Enclosure(s) (<i>please identify below:</i>) <small>stamped return postcard</small>
Remarks		
AUTHORIZATION TO CHARGE DEPOSIT ACCOUNT 08-1641 FOR ANY FEES DUE IN CONNECTION WITH THIS PAPER (Reference Atty Docket No. 39780-2730P1C63).		

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT

Firm or Individual name	DAPHNE REDDY, REG. NO. 53,507, HELLER EHRLMAN WHITE & McAULIFFE LLP		
Signature			
Date	DECEMBER 23, 2004	Customer Number:	35489

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated below and addressed to: Mail Stop **AMENDMENT**, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Express Mail Label EL 977 610 935 US

Typed or printed name	CHERYL ANN ROGERS		
Signature		Date	DECEMBER 23, 2004

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop , Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

12-27-04

AF/1647
JRW



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Avi J. ASHKENAZI, et al. Docket No.: 39780-2730 P1C63
Serial No.: 09/989,722 Group Art Unit: 1647
Filing Date: November 19, 2001 Examiner: Wegert, Sandra L.
For: **SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND
NUCLEIC ACIDS ENCODING THE SAME**

EXPRESS MAIL LABEL NO. EL 977 610 935 US

Date Mailed: DECEMBER 23, 2004

AMENDMENT AND RESPONSE TO OFFICE ACTION

MS: AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

In response to the Final Office Action mailed on October 1, 2004 in connection with the above-identified patent application, please enter the following amendments, and consider the following arguments. This response is timely filed within the shortened statutory period set for the response.

Amendments to the Claims are reflected in the listing of claims that begins on page 2 of this paper.

Remarks/Arguments begin on page 8 of this paper.